Bank of Montreal’s Cascadian Therapeutics, Inc. CASC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-2,426
| Closed | -$9K | – | 4486 |
|
|
2017
Q4 | $9K | Hold |
2,426
| – | – | ﹤0.01% | 3829 |
|
|
2017
Q3 | $10K | Hold |
2,426
| – | – | ﹤0.01% | 3715 |
|
|
2017
Q2 | $9K | Buy |
2,426
+2,174
| +863% | +$8.63K | ﹤0.01% | 3761 |
|
|
2017
Q1 | $1K | Buy |
252
+27
| +12% | +$113 | ﹤0.01% | 3929 |
|
|
2016
Q4 | $1K | Sell |
225
-3
| -1% | -$19 | ﹤0.01% | 4011 |
|
|
2016
Q3 | $2K | Hold |
228
| – | – | ﹤0.01% | 3892 |
|
|
2016
Q2 | $1K | Hold |
228
| – | – | ﹤0.01% | 4031 |
|
|
2016
Q1 | $2K | Buy |
228
+3
| +1% | +$23 | ﹤0.01% | 4012 |
|
|
2015
Q4 | $3K | Hold |
225
| – | – | ﹤0.01% | 3939 |
|
|
2015
Q3 | $4K | Sell |
225
-1,667
| -88% | -$34.2K | ﹤0.01% | 3711 |
|
|
2015
Q2 | $42K | Buy |
1,892
+1,667
| +741% | +$26.4K | ﹤0.01% | 3064 |
|
|
2015
Q1 | $2K | Hold |
225
| – | – | ﹤0.01% | 3823 |
|
|
2014
Q4 | $3K | Buy |
225
+14
| +7% | +$152 | ﹤0.01% | 3800 |
|
|
2014
Q3 | $2K | Sell |
211
-31
| -13% | -$474 | ﹤0.01% | 3926 |
|
|
2014
Q2 | $5K | Buy |
242
+17
| +8% | +$300 | ﹤0.01% | 4209 |
|
|
2014
Q1 | $4K | Sell |
225
-3
| -1% | -$49 | ﹤0.01% | 3848 |
|
|
2013
Q4 | $2K | Hold |
228
| – | – | ﹤0.01% | 3641 |
|
|
2013
Q3 | $3K | Buy |
228
+3
| +1% | +$32 | ﹤0.01% | 3653 |
|
|
2013
Q2 | $2K | Buy |
+225
| New | +$2.89K | ﹤0.01% | 3567 |
|
Bank of Montreal's CASC Position: Q1 2018 in Review
Bank of Montreal sold out of Cascadian Therapeutics, Inc. (CASC) in Q1 2018, closing a stake of 2,426 shares — an estimated $9K sold.
Bank of Montreal first reported a position in CASC in Q2 2013 and held it in 19 quarters. The position peaked at $42K in Q2 2015. 1 fund tracked by Wall St. Rank holds CASC as of Q1 2018.
- Bank of Montreal reported no remaining Cascadian Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
- Bank of Montreal sold 2,426 Cascadian Therapeutics, Inc. shares in Q1 2018, an estimated $9K.
- Bank of Montreal first reported a position in Cascadian Therapeutics, Inc. in Q2 2013 and held it in 19 quarters.
- Bank of Montreal's Cascadian Therapeutics, Inc. position peaked at $42K in Q2 2015.
- 1 fund tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q1 2018.
Based on Bank of Montreal's 13F filing for Q1 2018, filed 13 Apr 2018.